Korro Bio (KRRO) announced a submission to the Bellberry HREC for a Phase 1/2 clinical study of KRRO-110 for AATD. A Clinical Advisory Board, CAB, comprised of distinguished lung and liver researchers and experts in AATD has also been assembled to help guide the clinical development strategy for KRRO-110. Subject to approval by the HREC and acceptance of the clinical trial notification by Australia’s Therapeutic Goods Administration, Korro anticipates dosing the first participant in the Phase 1/2 study in the first quarter of 2025. An interim data readout for the Phase 1/2 study of KRRO-110 is anticipated in the second half of 2025, and completion of the study is expected in 2026.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio price target raised to $105 from $95 at RBC Capital
- Korro Bio initiated with a Strong Buy at Raymond James
- Korro Bio price target raised to $115 from $100 at H.C. Wainwright
- Wave Life Sciences price target raised to $20 from $16 at JonesResearch
- Stifel says early WVE-006 data de-risks DNA editing approaches like Beam’s ‘302